Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[99mTc]Tc-EDDA-HTK03180 is an investigational **PSMA-targeted radiopharmaceutical imaging agent** for prostate cancer SPECT imaging. It is a **technetium-99m labeled small-molecule tracer** built on a lysine-ureido-α-aminoadipic acid pharmacophore and incorporates a HYNIC chelator with tranexamic acid and 9-anthrylalanine; EDDA is used as a co-ligand for technetium coordination. The tracer is designed to bind **prostate-specific membrane antigen** on prostate cancer cells and enable lesion visualization by SPECT/CT. Based on the provided preclinical literature context, it has shown tumor uptake in PSMA-expressing LNCaP xenografts with lower spleen and salivary gland uptake than comparator PSMA SPECT tracers, and it remains in **preclinical research-stage development**.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [99mTc]Tc-EDDA-HTK03180.